MX351963B - Forma cristalina de una sal de ácido tiazolilacético sustituido y trietilamina. - Google Patents

Forma cristalina de una sal de ácido tiazolilacético sustituido y trietilamina.

Info

Publication number
MX351963B
MX351963B MX2015012146A MX2015012146A MX351963B MX 351963 B MX351963 B MX 351963B MX 2015012146 A MX2015012146 A MX 2015012146A MX 2015012146 A MX2015012146 A MX 2015012146A MX 351963 B MX351963 B MX 351963B
Authority
MX
Mexico
Prior art keywords
crystalline form
triethylamine salt
acid triethylamine
substituted
thiazolylacetic acid
Prior art date
Application number
MX2015012146A
Other languages
English (en)
Other versions
MX2015012146A (es
Inventor
Zhang Weijiang
R Tracey Michael
Lee Junning
Original Assignee
Theravance Biopharma Antibiotics Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip Llc filed Critical Theravance Biopharma Antibiotics Ip Llc
Publication of MX2015012146A publication Critical patent/MX2015012146A/es
Publication of MX351963B publication Critical patent/MX351963B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Una forma cristalina de una sal con trietilamina del ácido (2Z)-2-(2-amino-5-clorotiazol-4-il)-2-(3-N-tert-butoxicarbonilami nopropoxiimino)acético. También, procesos e intermediarios para preparar la forma cristalina. La forma cristalina es útil como intermediario para preparar antibióticos de glicopéptido reticulado-cefalosporina.
MX2015012146A 2013-03-13 2014-03-06 Forma cristalina de una sal de ácido tiazolilacético sustituido y trietilamina. MX351963B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779091P 2013-03-13 2013-03-13
PCT/US2014/021080 WO2014164187A1 (en) 2013-03-13 2014-03-06 Crystalline form of a substituted thiazolylacetic acid triethylamine salt

Publications (2)

Publication Number Publication Date
MX2015012146A MX2015012146A (es) 2015-11-25
MX351963B true MX351963B (es) 2017-11-06

Family

ID=50382685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012146A MX351963B (es) 2013-03-13 2014-03-06 Forma cristalina de una sal de ácido tiazolilacético sustituido y trietilamina.

Country Status (19)

Country Link
US (1) US9139542B2 (es)
EP (1) EP2970164B1 (es)
JP (2) JP6404309B2 (es)
KR (1) KR20150126368A (es)
CN (1) CN105121417B (es)
AU (1) AU2014249611B2 (es)
BR (1) BR112015022600A2 (es)
CA (1) CA2902724A1 (es)
EA (1) EA027911B1 (es)
ES (1) ES2634019T3 (es)
GE (1) GEP201706779B (es)
IL (1) IL240600A0 (es)
MD (1) MD4719C1 (es)
MX (1) MX351963B (es)
PH (1) PH12015502067A1 (es)
SG (1) SG11201507221VA (es)
TW (1) TWI627165B (es)
UA (1) UA115087C2 (es)
WO (1) WO2014164187A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12516036B2 (en) 2019-05-31 2026-01-06 Hyundai Pharm Co., Ltd. Crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284631A (en) 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
US4372952A (en) 1978-07-31 1983-02-08 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
DE2945248A1 (de) 1978-11-13 1980-05-22 Fujisawa Pharmaceutical Co Cephem-verbindungen, verfahren zu ihrer herstellung und sie enthaltende antibakterielle pharmazeutische mittel
EP0055465B1 (en) * 1980-12-31 1989-08-23 Fujisawa Pharmaceutical Co., Ltd. 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof
JP2519054B2 (ja) 1986-06-09 1996-07-31 武田薬品工業株式会社 新規セフェム化合物
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
JPH04221388A (ja) * 1990-12-20 1992-08-11 Asahi Chem Ind Co Ltd セファロスポリン化合物およびその製造法
TWI335332B (en) 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ITMI20012363A1 (it) 2001-11-09 2003-05-09 Antibioticos Spa Metodo per la sintesi di catene laterali di cefalosporine
EP1507796B1 (en) 2002-05-24 2012-05-02 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
GB0416379D0 (en) 2004-07-22 2004-08-25 Sandoz Ag Organic compounds
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative

Also Published As

Publication number Publication date
EA201591708A1 (ru) 2016-01-29
EA027911B1 (ru) 2017-09-29
HK1214596A1 (en) 2016-07-29
JP2016512257A (ja) 2016-04-25
MD4719B1 (ro) 2020-10-31
JP2018197256A (ja) 2018-12-13
US9139542B2 (en) 2015-09-22
PH12015502067B1 (en) 2016-01-25
AU2014249611B2 (en) 2017-12-21
TW201444810A (zh) 2014-12-01
US20140275554A1 (en) 2014-09-18
UA115087C2 (uk) 2017-09-11
ES2634019T3 (es) 2017-09-26
KR20150126368A (ko) 2015-11-11
CN105121417A (zh) 2015-12-02
SG11201507221VA (en) 2015-10-29
WO2014164187A1 (en) 2014-10-09
MD4719C1 (ro) 2021-05-31
EP2970164B1 (en) 2017-05-03
CA2902724A1 (en) 2014-10-09
CN105121417B (zh) 2017-11-17
BR112015022600A2 (pt) 2017-07-18
GEP201706779B (en) 2017-11-27
TWI627165B (zh) 2018-06-21
IL240600A0 (en) 2015-09-24
MX2015012146A (es) 2015-11-25
AU2014249611A1 (en) 2015-09-17
PH12015502067A1 (en) 2016-01-25
MD20150099A2 (ro) 2016-02-29
JP6404309B2 (ja) 2018-10-10
EP2970164A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
NZ726356A (en) Processes for preparing antiviral compounds
EP2970083A4 (en) Process to prepare levulinic acid
EP3290406A4 (en) Novel crystal of uracil compound
EP2999688A4 (en) Process to prepare levulinic acid
MX359673B (es) Preparacion de intermediarios de pirimidina utiles para la preparacion de maci tentano.
PL2903959T3 (pl) Sposób wytwarzania pochodnych kwasu cykloheksanopolikarboksylowego o małym udziale produktów ubocznych
MX362752B (es) Formas mórficas de ésteres de hexadeciloxipropil-fosfonato.
EP3017042A4 (en) Method for the purification of targeted nucleic acids from background nucleic acids
EP2968387A4 (en) Methods of synthesizing substituted purine compounds
EP3063120A4 (en) Process for preparation of herbicidal carboxylic acid salts
EP3592359A4 (en) CRYSTALLINE FORMS OF OBETICHOLIC ACID
EP3972585A4 (en) Bryostatin compounds for enhancement of immunotherapy
EP3199529A4 (en) Salt of dicarboxylic acid compound
EP3033331A4 (en) Process for the purification of diaminophenothiazinium compounds
EP3021849A4 (en) Novel crystalline forms of pemetrexed tromethamine salts
PH12015502067A1 (en) Crystalline form of a substituted thiazolylacetic acid triethylamine salt
EP3188737A4 (en) Crystalline form of eltrombopag free acid
IN2013MU04056A (es)
ZA201509355B (en) Novel ureido derivatives of naphthalenesulfonic acids
MX371011B (es) Intermediarios y métodos para sintetizar derivados de calicheamicina.
MX2014012822A (es) Proceso para elaborar derivados de naftiridina.
MX2015015346A (es) Procedimiento para la preparacion de intermediarios de acido boronico.
EP3250540B8 (en) Preparation of compounds from levulinic acid
EP3055283A4 (en) Process to prepare levulinic acid

Legal Events

Date Code Title Description
FG Grant or registration